Is Pfizer (PFE) a Buy Right Now?
A plain-English read on Pfizer stock — what the chart and the numbers are saying today, with no jargon and no hype.
We've already run the numbers on PFE.
Our AI has a Buy, Hold or Be Careful call on Pfizer right now — in plain English, why, the 4 factors moving it, and the bottom line. That's the part a beginner actually needs, and it's the one thing on this page we don't give away for free.
Includes this signal plus the rest of the 35-tool platform. Cancel anytime — no contract.
What Pfizer actually does
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer by the numbers
Wall Street consensus on PFE is Buy. That is the analyst community's view, shown for context — it is not our read and not a recommendation.
Who owns Pfizer?
Institutions — pension funds, asset managers, index providers — hold 69.1% of PFE, and the concentration matters: the largest single holder alone controls 9.29% of the company.
| Holder | Shares | % held |
|---|---|---|
| 529.67M | 9.29% | |
| 372.15M | 6.53% | |
| 307.09M | 5.39% |
Names withheld — plus 3 more records not shown.
See who owns itWhat Pfizer insiders have been doing
Executives and directors must disclose their own trades in company stock. Of the last 6 disclosed transactions we hold for Pfizer, 2 were sales and 3 were open-market purchases; the other 1 was awards, vesting or option exercises rather than a decision to buy or sell. Insiders sell for many ordinary reasons — scheduled plans, tax, diversification — so a sale is not by itself a signal.
| Insider | Date | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-12 | BUY | 38.0K | $1.0M | |
| 2026-08-05 | SELL | 3.3K | $83.3K | |
| 2026-08-05 | BUY | 39.2K | $998.8K |
Names withheld — plus 3 more records not shown.
See which insidersThe numbers behind the read
Who in Washington has been trading PFE?
Members of Congress must disclose trades over $1,000 within 45 days under the STOCK Act. At least 25 disclosures name PFE — filed by 11 separate members or more and worth $236K–$890K combined (filings report bands, never exact amounts). 10 purchase-side, 15 sale-side, most recently on 2026-03-13.
| Member | Date | Action | Amount filed |
|---|---|---|---|
| 2026-03-13 | SELL | $1,001 - $15,000 | |
| 2026-02-10 | BUY | $1,001 - $15,000 | |
| 2026-02-03 | BUY | $15,001 - $50,000 |
Names withheld — plus 22 more records not shown.
See which membersDon't guess. Practice this trade first.
Buy it with virtual cash and watch how it plays out — before a dollar of your own is on the line.
Practice PFE risk-free in your paper portfolioPaper trading, the AI Read & live indicators are inside a Money GPS membership — one price, the whole platform.
Important disclaimer
This page is for educational and informational purposes only and is not financial, investment, tax, or legal advice, nor a recommendation, offer, or solicitation to buy, sell, or hold Pfizer (PFE) or any other security. The Money GPS is not a registered investment adviser, broker-dealer, or financial planner, and no content here should be relied upon to make an investment decision.
The verdict, indicators, and commentary are generated automatically — in part using AI — from third-party market data (via Yahoo Finance) that may be delayed, incomplete, or inaccurate, and is provided “as is” without any warranty. Figures reflect the market as of 2026-09-17 and change constantly; the read above may already be out of date. A “Buy,” “Hold,” or “Be Careful” label is a simplified, rules-based signal for beginners — not a price target or a guarantee of any outcome.
All investing involves risk, including the possible loss of your entire principal. Past performance and historical patterns do not guarantee future results. Always do your own research and consult a licensed financial professional who knows your personal circumstances before investing. You are solely responsible for your own investment decisions. The Money GPS and its authors may hold positions in the securities discussed and accept no liability for any loss arising from the use of this information.